The Recall Desk
SevereFDA (Drugs)·D-0144-2024·Announced 2023-12-13

FDA Recalls SANDIMMUNE Oral Solution Due to Crystallization

Novartis Pharmaceuticals is recalling SANDIMMUNE Oral Solution (cyclosporine 100 mg/mL) due to crystallization found in bottles. The affected lots were distributed nationwide.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: This is an FDA Class I recall, which warrants a Severe rating (score 4) per regulatory criteria. No illnesses or deaths have been reported; however, the FDA's Class I classification indicates a serious hazard to health.

Plain-English summary

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL is being recalled. The medication in affected bottles was determined to contain crystallization.

The recall involves 6,997 bottles distributed nationwide within the United States. The affected lot numbers are FX001500 and FX001582, with expiration date 09/30/2024. The medication is manufactured by DELPHARM Huningue S.A.S. in Huningue, France and distributed by Novartis Pharmaceuticals Corporation in East Hanover, New Jersey. The National Drug Code (NDC) is 0078-0110-22.

This is an FDA Class I recall. Additional information is available from the FDA at https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls using recall number D-0144-2024.

The recalled product

Product
SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22
Manufacturer
Novartis Pharmaceuticals Corporation
Category
Drug
Hazard
  • crystallization

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot #: FX001500
  • FX001582
  • Exp. 09/30/2024

Distribution

Distributed nationwide across the United States.